|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.9000 - 0.9400|
|52 Week Range||0.8900 - 1.9500|
|Beta (5Y Monthly)||2.05|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has hired WSI PBG, LLC (WSI), a Michigan based firm specializing in creating access for and selling pharmaceuticals, medical diagnostics and durable medical equipment in the Veterans Administration (VA), Military Health System (MHS) and Indian Healthcare System (IHS). WSI will have 6 Federal Account Managers promoting Strontium89 (Strontium Chloride Sr-89 Injection, USP) within 76 VA and MHS medical centers across the US.
Q BioMed Inc. (OTCQB: QBIO), announced today that it has signed a securities purchase agreement ("Transaction") with Aedesius Holdings Ltd (AedesiusOne), a privately owned United Kingdom based healthcare and technology aggregator. AedesiusOne is run by Geoffrey Fatzinger, our Global Head of Regulatory Affairs. The agreement gives AedesiusOne the opportunity to buy approximately 43% of the outstanding QBIO shares for an aggregate of $30,000,000. The Transaction is structured as an initial investment of $5,000,000 with an additional $15,000,000 by September 30, 2021 with 50% warrant coverage allowing an additional $10,000,000 investment within 120 days. The Unit Price is set at $1.25 per share, a 31% premium to yesterday's closing price. The investor is expected to ultimately take a seat on the Board.
Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, updates shareholders.